Glenmede Trust’s Albireo Pharma Inc ALBO Stock Holding History

Glenmede Trust’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-101	Closed	-$3K	–	2424
2020 Q3	$3K	Buy	101 +76	+304%	+$2.21K	﹤0.01%	2224
2020 Q2	$0	Buy	+25	New	+$590	﹤0.01%	2676

Other funds holding ALBO

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Glenmede Trust's ALBO Position: Q4 2020 in Review

Glenmede Trust sold out of Albireo Pharma Inc (ALBO) in Q4 2020, closing a stake of 101 shares — an estimated $3K sold.

Glenmede Trust first reported a position in ALBO in Q2 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 107 funds tracked by Wall St. Rank hold ALBO as of Q4 2020.

Glenmede Trust reported no remaining Albireo Pharma Inc position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 101 Albireo Pharma Inc shares in Q4 2020, an estimated $3K.
Glenmede Trust first reported a position in Albireo Pharma Inc in Q2 2020 and held it in 2 quarters.
Glenmede Trust's Albireo Pharma Inc position peaked at $3K in Q3 2020.
107 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.